In this week's episode, Dr Ankur Kalra welcomes authors Dr Srihari Naidu and Lindsay Davis to discuss their newly published children's book, Lindsay's Big Heart. A leading interventional cardiologist, Dr Naidu, and patient advocate, Ms Davis, have collaborated to bring the complex heart condition hypertrophic cardiomyopathy (HCM) to life for young readers.
Lindsay Davis shares her personal journey with HCM, offering a firsthand perspective on the challenges and triumphs of living with the condition. Dr Srihari Naidu discusses the importance of translating complex medical information into a format that children can understand and appreciate. As a parent himself, he was inspired to create a resource that would help families navigate the complexities of HCM.
The authors share the challenges and rewards of bringing Lindsay's Big Heart to publication, from securing a publisher to finalising the illustrations. They believe that the book can help children feel more informed and empowered, reducing fear and anxiety associated with HCM. Additionally, they hope the book will raise awareness of the condition and encourage early diagnosis and treatment.
Join us as we delve into the inspiration behind the book, the writing process, and the importance of accurate and engaging medical education for children.
They talk about AI assisted consultation, learning pathways incorporating simulators for early career practitioners and the Flying Eye Hospital. Dr Cherwek shares his experiences about working with local teams globally and the work that goes into setting up trials across the world.
Dr Ankur Kalra’s guests this week are Dr Martha Gulati, internationally recognized cardiologist specializing in Women and Heart Disease, Heart Disease Prevention and Dr Devesh Rai, first year cardiology fellow at Rochester General Hospital.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.